Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00800501 | A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | 18 | — | — | Dec 1, 2008 | Jun 1, 2011 | Dec 6, 2011 | 1 | Belgium |
| Arm | Type | Description |
|---|---|---|
| sNN0029 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| sNN0029 | DRUG | Continuous ICV infusion at one of three dose levels |
| Placebo | DRUG | Continuous ICV infusion |
Inclusion Criteria: 1. Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised WFN El Escorial criteria. 2. Age 18 to 75 years inclusive. 3. If patients are being treated with riluzole, they must have been on a stable do...